DE2349922A1 - Neue fusidinsaeurekonjugate, verfahren zu deren herstellung und pharmazeutische mischungen mit einem gehalt an diesen fusidinsaeurekonjugaten - Google Patents
Neue fusidinsaeurekonjugate, verfahren zu deren herstellung und pharmazeutische mischungen mit einem gehalt an diesen fusidinsaeurekonjugatenInfo
- Publication number
- DE2349922A1 DE2349922A1 DE19732349922 DE2349922A DE2349922A1 DE 2349922 A1 DE2349922 A1 DE 2349922A1 DE 19732349922 DE19732349922 DE 19732349922 DE 2349922 A DE2349922 A DE 2349922A DE 2349922 A1 DE2349922 A1 DE 2349922A1
- Authority
- DE
- Germany
- Prior art keywords
- acid
- fusidic acid
- compounds
- conjugates
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 title claims description 15
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 title claims description 12
- 229960004675 fusidic acid Drugs 0.000 title claims description 12
- 238000000034 method Methods 0.000 title claims description 10
- 239000000203 mixture Substances 0.000 title description 23
- 238000004519 manufacturing process Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 41
- 239000002253 acid Substances 0.000 claims description 24
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052708 sodium Inorganic materials 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 11
- 239000004471 Glycine Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 229960003080 taurine Drugs 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- IWQPOPSAISBUAH-VOVMJQHHSA-M sodium;2-[[(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyl-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylheptanoyl]amino]ethanesulfonate Chemical compound [Na+].C1C[C@@H](O)[C@@H](C)[C@@H]2CC[C@]3(C)[C@@]4(C)C[C@H](C(C)=O)/C(=C(C(=O)NCCS([O-])(=O)=O)/CCCC(C)C)[C@@H]4C[C@@H](O)[C@H]3[C@]21C IWQPOPSAISBUAH-VOVMJQHHSA-M 0.000 claims description 3
- 230000021736 acetylation Effects 0.000 claims description 2
- 238000006640 acetylation reaction Methods 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 150000008064 anhydrides Chemical class 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 238000006748 scratching Methods 0.000 description 7
- 230000002393 scratching effect Effects 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- -1 alkali metal salts Chemical class 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- RDDQYPXUIDIYTL-AREPUUQJSA-N 2-[[(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylheptanoyl]amino]acetic acid Chemical compound C1C[C@@H](O)[C@@H](C)[C@@H]2CC[C@]3(C)[C@@]4(C)C[C@H](OC(C)=O)/C(=C(C(=O)NCC(O)=O)/CCCC(C)C)[C@@H]4C[C@@H](O)[C@H]3[C@]21C RDDQYPXUIDIYTL-AREPUUQJSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002021 butanolic extract Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-O dicyclohexylazanium Chemical compound C1CCCCC1[NH2+]C1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-O 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Inorganic materials [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- HVAMZGADVCBITI-UHFFFAOYSA-M pent-4-enoate Chemical compound [O-]C(=O)CCC=C HVAMZGADVCBITI-UHFFFAOYSA-M 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB4635172 | 1972-10-06 | ||
| GB4098173A GB1447489A (en) | 1972-10-06 | 1973-08-30 | Fusidic acid conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2349922A1 true DE2349922A1 (de) | 1974-04-11 |
Family
ID=26264559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19732349922 Pending DE2349922A1 (de) | 1972-10-06 | 1973-10-04 | Neue fusidinsaeurekonjugate, verfahren zu deren herstellung und pharmazeutische mischungen mit einem gehalt an diesen fusidinsaeurekonjugaten |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US3867413A (enExample) |
| JP (1) | JPS49132064A (enExample) |
| AR (1) | AR199490A1 (enExample) |
| AT (1) | AT327384B (enExample) |
| AU (1) | AU470769B2 (enExample) |
| CA (1) | CA1017324A (enExample) |
| CH (1) | CH584238A5 (enExample) |
| DD (1) | DD106641A5 (enExample) |
| DE (1) | DE2349922A1 (enExample) |
| DK (1) | DK131348B (enExample) |
| ES (1) | ES419226A1 (enExample) |
| FI (1) | FI52098C (enExample) |
| FR (1) | FR2201892B1 (enExample) |
| GB (1) | GB1447489A (enExample) |
| HU (1) | HU166734B (enExample) |
| IE (1) | IE38258B1 (enExample) |
| IL (1) | IL43287A (enExample) |
| LU (1) | LU68566A1 (enExample) |
| NL (1) | NL7313732A (enExample) |
| PH (1) | PH10337A (enExample) |
| SE (1) | SE395705B (enExample) |
| SU (1) | SU489316A3 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1490852A (en) * | 1974-09-12 | 1977-11-02 | Leo Pharm Prod Ltd | Fusidic acid derivatives |
| IE44263B1 (en) * | 1975-12-03 | 1981-09-23 | Leo Pharm Prod Ltd | New fusidic acid derivatives |
| US4959358A (en) * | 1983-06-06 | 1990-09-25 | Beth Israel Hospital Assn. | Drug administration |
| US4548922A (en) * | 1983-06-06 | 1985-10-22 | Beth Israel Hospital | Drug administration |
| US4746508A (en) * | 1983-06-06 | 1988-05-24 | Beth Israel Hospital Assn. | Drug administration |
| US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| KR100280367B1 (ko) * | 1999-02-05 | 2001-01-15 | 조생현 | 푸시딘산의 정제방법 |
| US20100239655A1 (en) * | 2004-12-09 | 2010-09-23 | Georgia Levis | Taurine-based compositions and therapeutic methods |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1167643A (fr) * | 1955-04-13 | 1958-11-27 | Chimiotherapie Lab Franc | Nouveaux amides cholaniques et leur procédé d'obtention |
| GB963499A (en) * | 1961-11-15 | 1964-07-08 | Loevens Kemiske Fab | Dihydrofusidic acid and process for preparation thereof |
| US3622669A (en) * | 1967-10-23 | 1971-11-23 | Merck & Co Inc | 5{62 -taurocholenic acids and 5{62 -taurocholadienic acids in compositions for reducing the concentration of cholesterol and liads in blood serum |
| US3708510A (en) * | 1970-09-03 | 1973-01-02 | Merck & Co Inc | Amides of cholanic acid,cholenic acid,and choladienic acid |
-
1973
- 1973-08-30 GB GB4098173A patent/GB1447489A/en not_active Expired
- 1973-09-18 IE IE1662/73A patent/IE38258B1/xx unknown
- 1973-09-21 IL IL43287A patent/IL43287A/en unknown
- 1973-09-24 US US400348A patent/US3867413A/en not_active Expired - Lifetime
- 1973-09-26 CA CA181,959A patent/CA1017324A/en not_active Expired
- 1973-09-27 PH PH15058A patent/PH10337A/en unknown
- 1973-09-27 AT AT830173A patent/AT327384B/de not_active IP Right Cessation
- 1973-10-02 ES ES419226A patent/ES419226A1/es not_active Expired
- 1973-10-03 FI FI733080A patent/FI52098C/fi active
- 1973-10-04 DE DE19732349922 patent/DE2349922A1/de active Pending
- 1973-10-04 DD DD173875A patent/DD106641A5/xx unknown
- 1973-10-04 DK DK538673AA patent/DK131348B/da unknown
- 1973-10-04 JP JP48111079A patent/JPS49132064A/ja active Pending
- 1973-10-04 CH CH1417373A patent/CH584238A5/xx not_active IP Right Cessation
- 1973-10-05 SE SE7313612A patent/SE395705B/xx unknown
- 1973-10-05 NL NL7313732A patent/NL7313732A/xx unknown
- 1973-10-05 SU SU1960938A patent/SU489316A3/ru active
- 1973-10-05 HU HULE723A patent/HU166734B/hu unknown
- 1973-10-05 FR FR7335730A patent/FR2201892B1/fr not_active Expired
- 1973-10-05 AR AR250388A patent/AR199490A1/es active
- 1973-10-05 LU LU68566A patent/LU68566A1/xx unknown
- 1973-10-05 AU AU61070/73A patent/AU470769B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FI52098B (enExample) | 1977-02-28 |
| CA1017324A (en) | 1977-09-13 |
| AT327384B (de) | 1976-01-26 |
| DD106641A5 (enExample) | 1974-06-20 |
| SE395705B (sv) | 1977-08-22 |
| PH10337A (en) | 1976-12-09 |
| DK131348C (enExample) | 1975-11-24 |
| FR2201892B1 (enExample) | 1977-01-28 |
| DK131348B (da) | 1975-06-30 |
| CH584238A5 (enExample) | 1977-01-31 |
| FR2201892A1 (enExample) | 1974-05-03 |
| HU166734B (enExample) | 1975-05-28 |
| ES419226A1 (es) | 1976-06-16 |
| AU470769B2 (en) | 1976-03-25 |
| AR199490A1 (es) | 1974-09-09 |
| GB1447489A (en) | 1976-08-25 |
| JPS49132064A (enExample) | 1974-12-18 |
| IL43287A (en) | 1977-04-29 |
| IE38258L (en) | 1974-04-06 |
| SU489316A3 (ru) | 1975-10-25 |
| IE38258B1 (en) | 1978-02-01 |
| FI52098C (fi) | 1977-06-10 |
| NL7313732A (enExample) | 1974-04-09 |
| US3867413A (en) | 1975-02-18 |
| AU6107073A (en) | 1975-04-10 |
| LU68566A1 (enExample) | 1973-12-14 |
| ATA830173A (de) | 1975-04-15 |
| IL43287A0 (en) | 1973-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0573848B1 (de) | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel | |
| EP0624594B1 (de) | Monomere Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel | |
| EP0489423A1 (de) | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindung als Arzneimittel | |
| DE2634288B2 (enExample) | ||
| CH643806A5 (de) | Verfahren zur herstellung neuer ml-236b-carbonsaeurederivate. | |
| CH656134A5 (de) | 26,26,26,27,27,27-hexafluor-cholesterine. | |
| CH647244A5 (de) | Analoga von lincomycin und clindamycin. | |
| DE2349922A1 (de) | Neue fusidinsaeurekonjugate, verfahren zu deren herstellung und pharmazeutische mischungen mit einem gehalt an diesen fusidinsaeurekonjugaten | |
| DE2643936A1 (de) | Arzneimittel mit erythropoietischer wirksamkeit | |
| DE2653257A1 (de) | Neue kondensierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als entzuendungshemmende und die gerinnung des blutes hemmende arzneimittel | |
| CH637405A5 (de) | Verfahren zur herstellung von 17-alpha-pregnanderivaten. | |
| CH617183A5 (enExample) | ||
| DE2337067A1 (de) | Indensaeure-glucuronide | |
| DE2112057A1 (de) | Neue Penicillinester | |
| EP0100516A2 (de) | 3-Beta-(3'-(Carboxypropionyloxy))-ursa-9(11),12-dien-28-carbonsäure sowie ihre Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2054142A1 (de) | Pyridinsulfonsauren | |
| DE2457107A1 (de) | Salze und komplexe von lysozym und lysozymderivate | |
| DE2452501A1 (de) | Erythrodiolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel | |
| DE2462592C2 (de) | 3-(0-Äthyl)-6-desoxy-6-azido-7,8-dihydro-isomorphin, dessen Herstellung und diese Verbindung enthaltende Arzneimittel | |
| DE2357778C3 (de) | Neue Ester von 21-Mercaptosteroiden, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
| CH526526A (de) | Verfahren zur Herstellung eines neuen 6a-Methyl-19-nor-progesterons | |
| DE3153733C2 (de) | Thiocarnitinhydrochloride | |
| DE2145686C3 (de) | 2-Chlor-S-sulfamylbenzoesäurederivate, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten | |
| DE3150084C2 (de) | Verfahren zur Herstellung von Thiocarnitin-Halogeniden und diese enthaltende Arzneimittelzubereitungen | |
| DE1643036C3 (de) | Neue 11 beta-Halogensterolde, diese enthaltende Arzneimittel sowie Verfahren zu ihrer Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee |